← Back to all trials
Terminated
NCT05932212
AK104 for Recurrent or Metastatic Vulvar Cancer
Conditions: Vulvar Cancer
Sex: Female
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 20
Sponsor: Akeso
Location: Clinical oncology school of Fujian Medical University, Fujian Cancer Hospital Fuzhou Fujian
Summary
This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.
Eligibility Criteria
Inclusion Criteria:
Age \>=18 and \
Source: ClinicalTrials.gov (NCT05932212). StuddyBuddy aggregates publicly available trial information.